Unlock Better AAV Therapies with Flow Imaging Microscopy

Discover Critical Quality Attributes You Might Be Missing

Adeno-associated virus (AAV) therapies are at the forefront of gene therapy innovation—but ensuring their safety, efficacy, and regulatory compliance depends on more than just viral titer, full-empty capsid ratio, and potency. One often-overlooked critical quality attribute (CQA)? Subvisible particles.

Subvisible particles such as AAV aggregates, container-closure derived particles, and contaminants can compromise product quality and potentially lead to immune responses. Monitoring them is essential.

Real Data. Real Insights.

Dive into a real-world case study:
How do formulation and stress conditions affect AAV stability? Learn how FlowCam detected changes in AAV aggregate concentrations, sizes, and morphologies and how this data can inform rational formulation design.

📄 Download the Application Note

“Monitoring Subvisible Particles in AAV Therapies with Flow Imaging Microscopy”

See how advanced particle characterization can:

✔ Improve formulation strategies
✔ Support regulatory compliance (USP <788> and <789>)
✔ Enhance therapeutic safety and performance